As the Australian market navigates a mixed landscape with tech stocks showing resilience amidst broader sector fluctuations, investors are keenly observing how economic indicators and global events influence small-cap performance. In this environment, identifying high growth tech stocks involves looking for companies that demonstrate robust innovation and adaptability to changing market dynamics.

Top 10 High Growth Tech Companies In Australia

Name Revenue Growth Earnings Growth Growth Rating Pureprofile 10.51% 37.56% ★★★★★☆ Pro Medicus 19.70% 21.17% ★★★★★☆ Kinatico 13.27% 42.29% ★★★★☆☆ Immutep 45.34% 29.54% ★★★★★☆ Clinuvel Pharmaceuticals 22.02% 23.88% ★★★★★☆ BlinkLab 104.90% 101.40% ★★★★★★ Wrkr 52.49% 88.00% ★★★★★★ Artrya 50.54% 61.25% ★★★★★☆ FINEOS Corporation Holdings 9.22% 57.85% ★★★★☆☆ Ai-Media Technologies 16.83% 94.47% ★★★★☆☆

Click here to see the full list of 23 stocks from our ASX High Growth Tech and AI Stocks screener.

Here's a peek at a few of the choices from the screener.

Data#3

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Data#3 Limited is an Australian company that offers comprehensive information technology solutions and services, with a market capitalization of approximately A$1.40 billion.

Operations: The company generates revenue from three primary segments: Services (A$271.91 million), Software Solutions (A$72.61 million), and Infrastructure Solutions (A$508.14 million).

Data#3, a notable entity in Australia's tech landscape, is demonstrating robust growth with a 23.2% annual increase in revenue, outpacing the Australian market's average of 5.9%. This growth is supported by an impressive forecasted Return on Equity of 58.7% in three years, signaling strong future profitability. Despite earnings projected to grow at 9.8% per year—slightly below the national market average of 12%—the company maintains a positive trajectory with high-quality earnings and free cash flow positivity. The recent Annual General Meeting highlighted strategic leadership appointments and shareholder engagement, underscoring Data#3’s commitment to governance and sustained growth in the high-tech sector.

Unlock comprehensive insights into our analysis of Data#3 stock in this health report. Learn about Data#3's historical performance.ASX:DTL Revenue and Expenses Breakdown as at Dec 2025

Pro Medicus

Simply Wall St Growth Rating: ★★★★★☆

Overview: Pro Medicus Limited is a healthcare informatics company that develops and supplies imaging software and radiology information system services to hospitals, imaging centers, and healthcare groups across Australia, North America, and Europe, with a market capitalization of A$24.42 billion.

Story Continues

Operations: The company generates revenue primarily from producing integrated software applications for the healthcare industry, amounting to A$212.98 million. It operates across Australia, North America, and Europe, focusing on healthcare imaging and radiology information systems.

Pro Medicus, amidst a strategic expansion phase, is actively pursuing mergers and acquisitions to enhance its innovative product suite. This approach not only reinforces its market leadership but also aligns with its recent 19.7% annual revenue growth, outstripping the broader Australian market's 5.9%. With earnings surging by 21.2% annually and R&D investments sharpening competitive edges, the firm's forward-looking agenda was underscored at their Annual General Meeting where future strategies and leadership roles were key discussions points. These moves are pivotal in sustaining Pro Medicus' trajectory in the high-tech sector of healthcare services, promising robust future prospects as indicated by a projected Return on Equity of 50.7% in three years.

Take a closer look at Pro Medicus' potential here in our health report. Explore historical data to track Pro Medicus' performance over time in our Past section.ASX:PME Earnings and Revenue Growth as at Dec 2025

Technology One

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Technology One Limited develops, markets, sells, implements, and supports integrated enterprise business software solutions in Australia and internationally with a market cap of A$8.94 billion.

Operations: With a market cap of A$8.94 billion, Technology One Limited generates revenue primarily from its software segment, contributing A$407.32 million, followed by corporate and consulting segments at A$95.01 million and A$96.18 million respectively.

Technology One, a standout in Australia's tech landscape, is making strategic moves through acquisitions to bolster its innovative capabilities, notably with the addition of CourseLoop. This approach is underpinned by robust financials with revenue and earnings growth at 11.6% and 14.6% per annum respectively, outpacing the broader market's performance. The company's commitment to R&D is evident from its expenditure trends which significantly contribute to its competitive edge in software solutions. With a forward-looking Return on Equity projected at 39.6%, Technology One is not just keeping pace but setting benchmarks within the tech sector, supported further by recent inclusion in major indices like S&P/ASX 50 and S&P Global 1200 as of September 2025.

Click here to discover the nuances of Technology One with our detailed analytical health report. Gain insights into Technology One's past trends and performance with our Past report.ASX:TNE Revenue and Expenses Breakdown as at Dec 2025

Taking Advantage

Dive into all 23 of the ASX High Growth Tech and AI Stocks we have identified here. Already own these companies? Link your portfolio to Simply Wall St and get alerts on any new warning signs to your stocks. Take control of your financial future using Simply Wall St, offering free, in-depth knowledge of international markets to every investor.

Ready To Venture Into Other Investment Styles?

Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include ASX:DTL ASX:PME and ASX:TNE.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]

View Comments